FOLLOWING CURATIVE RESECTION OF COLORECTAL-CARCINOMA, PORTAL CHEMOTHERAPY IS ESPECIALLY EFFECTIVE IN PATIENTS NOT RECEIVING BLOOD-TRANSFUSIONS

被引：0
|
作者：
HARDER, F
LAFFER, U
BERRES, M
JAGGI, P
METZGER, U
机构：
[1] UNIV ZURICH,CHIRURG KLIN,CH-8006 ZURICH,SWITZERLAND
[2] CIBA GEIGY AG,STAT ABT,CH-4002 BASEL,SWITZERLAND
来源：
CHIRURG | 1990年 / 61卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：280 / 285
页数：6
相关论文
共 35 条
  • [31] Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial
    Zhang, Rong-xin
    Wu, Xiao-jun
    Wan, De-sen
    Lin, Jun-zhong
    Ding, Pei-rong
    Liao, Le-en
    Lei, Jian
    Lu, Zhen-hai
    Li, Li-ren
    Chen, Gong
    Kong, Ling-heng
    Wang, Fu-long
    Zhang, Jian
    Fan, Wen-hua
    Jiang, Wu
    Zhou, Wen-hao
    Li, Cong
    Li, Yuan
    Li, Xue-ying
    Peng, Jian-hong
    Pan, Zhi-zhong
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (10) : 6622 - 6631
  • [32] Patterns of Failure Following Curative Treatment for Oral Cavity Squamous Cell Carcinoma, in Patients Receiving Post-Operative Radiotherapy plus /- Chemotherapy, an Institutional Experience
    Ko, Huaising Cindy
    Witek, Matthew E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E33 - E33
  • [33] INCREASED FREQUENCY OF CHROMOSOMAL DAMAGE IN PERIPHERAL-BLOOD LYMPHOCYTES UP TO 9 YEARS FOLLOWING CURATIVE CHEMOTHERAPY OF PATIENTS WITH TESTICULAR-CARCINOMA
    OSANTO, S
    THIJSSEN, JCP
    WOLDERING, VM
    VANRIJN, JLS
    NATARAJAN, AT
    TATES, AD
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 1991, 17 (02) : 71 - 78
  • [34] A commentary on 'Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): a randomized, multicenter, prospective, phase III trial'
    Yin, Zongbao
    Zhang, Gang
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (12) : 8177 - 8178
  • [35] Factors affecting progression-free survival (PFS) for patients with metastatic colorectal cancer (mCRC) receiving regorafenib or for patients after re-challenge previously effective chemotherapy (CT) regimens in third or following lines
    Kuzmina, E.
    Fedyanin, M.
    Pokataev, I.
    ANNALS OF ONCOLOGY, 2023, 34 : S156 - S156
1234